NT 10-K 1 bion_nt10k.htm NT 10-K bion_nt10k.htm






FORM 12b-25




Commission File Number: 333-229399


(Check One):

☒ Form 10-K    ☐ Form 20-F    ☐ Form 11-K    ☐ Form 10-Q    ☐ Form 10-D    ☐ Form N-SAR    ☐ Form N-CSR


For Period Ended: December 31, 2021




☐    Transition Report on Form 10-K


☐    Transition Report on Form 20-F


☐    Transition Report on Form 11-K


☐    Transition Report on Form 10-Q


☐    Transition Report on Form N-SAR



For the Transition Period Ended: ______________________


Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.


If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: _________________________________




BioNexus Gene Lab Corp.

Full Name of Registrant



Former Name if Applicable


Unit 02, Level 10, Tower B, Avenue 3,

The Vertical Business Suite II,

Bangar South

No. 8 Jalan Kerinchi

Address of Principal Executive Office (Street and Number)


Kuala Lumpur, Malaysia 59200

City, State and Zip Code





PART II -- RULES 12b-25(b) AND (c)


If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b‑25(b), the following should be completed. (Check box if appropriate)



The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;




The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N‑SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or the subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and




The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.




State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

(Attach extra sheets if needed)


Bionexus Gene Lab Corp. (the “Company”) is filing this Form 12b-25 to report that it is unable to file its Annual Report on Form 10-K for the period ended December 31, 2021 within the prescribed time period without unreasonable effort or expense because the financial statements could not be completed in time to timely file. The Company will file the Form 10-K by the extension date.





Name and telephone number of person to contact in regard to this notification


Chi Yuen (George) Leong, President


+60 1221-26512



(Telephone Number)



Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

☒ Yes    ☐ No



Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

☐ Yes    ☒ No



If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.






BioNexus Gene Lab Corp.

(Name of Registrant as Specified in Charter)


has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.


Date: March 31, 2022


/s/ Chi Yuen (George) Leong




Chi Yuen (George) Leong